Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Thermo Fisher Scientific Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Short-term obligations and current maturities of long-term obligations	2,214)	3,609)	5,579)	2,537)	2,628)
Accounts payable	3,079)	2,872)	3,381)	2,867)	2,175)
Accrued payroll and employee benefits	1,988)	1,596)	2,095)	2,427)	1,916)
Contract liabilities	2,852)	2,689)	2,601)	2,655)	1,271)
Other accrued expenses	3,199)	3,246)	3,354)	2,950)	2,314)
Current liabilities	13,332)	14,012)	17,010)	13,436)	10,304)
Deferred income taxes	1,268)	1,922)	2,849)	3,837)	1,794)
Other long-term liabilities	3,989)	4,642)	4,238)	4,540)	3,330)
Long-term obligations, excluding current maturities	29,061)	31,308)	28,909)	32,333)	19,107)
Long-term liabilities	34,318)	37,872)	35,996)	40,710)	24,231)
Total liabilities	47,650)	51,884)	53,006)	54,146)	34,535)
Redeemable noncontrolling interest	120)	118)	116)	122)	—)
Preferred stock, $100 par value; none issued	—)	—)	—)	—)	—)
Common stock, $1 par value	444)	442)	441)	439)	437)
Capital in excess of par value	17,962)	17,286)	16,743)	16,174)	15,579)
Retained earnings	53,101)	47,364)	41,910)	35,431)	28,116)
Treasury stock at cost	(19,226)	(15,133)	(12,017)	(8,922)	(6,818)
Accumulated other comprehensive loss	(2,697)	(3,224)	(3,099)	(2,329)	(2,807)
Total Thermo Fisher Scientific Inc. shareholders’ equity	49,584)	46,735)	43,978)	40,793)	34,507)
Noncontrolling interests	(33)	(11)	54)	62)	10)
Total equity	49,551)	46,724)	44,032)	40,855)	34,517)
Total liabilities, redeemable noncontrolling interest and equity	97,321)	98,726)	97,154)	95,123)	69,052)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Thermo Fisher Scientific Inc. current liabilities decreased from 2022 to 2023 and from 2023 to 2024.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Thermo Fisher Scientific Inc. long-term liabilities increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Thermo Fisher Scientific Inc. total liabilities decreased from 2022 to 2023 and from 2023 to 2024.
Total Thermo Fisher Scientific Inc. shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Thermo Fisher Scientific Inc. total Thermo Fisher Scientific Inc. shareholders’ equity increased from 2022 to 2023 and from 2023 to 2024.

Thermo Fisher Scientific Inc. (NYSE:TMO)

Balance Sheet: Liabilities and Stockholders’ Equity